Resverlogix Corp.

Welcome To The Resverlogix HUB On AGORACOM Edit this title from the Fast Facts Section
Home Videos Research Press Release Q&A Discussion
Discussion
Back     Next
Threads Posts
Pfizer's PCSK9 Inhibitor bococizumab - further development being scrapped
Resverlogix Corp.
almost 8 years ago
5

Based on this article, it seems PCSK9 might not be the greatest road to travel either.

Pfizer said bococizumab gradually lost its potency in reducing "bad" LDL cholesterol and caused more irritation at the injection site than similar recently approved drugs.

Also quite costly. Wonder if Amgen and Regeneron's drugs will see a similar fate.

https://ca.finance.yahoo.com/news/pfizer-quarterly-profit-falls-38-percent-110306205--finance.html

Maybe another reason to renew interest in the RVX approaches to improving CVD health.

masila

Back     Next
Please login to post a reply
masila
City
Calgary
Rank
Treasurer
Activity Points
500
Rating
Your Rating
Please Log In to Vote
Date Joined
05/12/2015
Social Links
Private Message
Resverlogix Corp.
Stock Quotes
Symbol
RVX
Exchange
TSX
Shares
105,207,816
Industry
Technology & Medical
Website
resverlogix.com/
Create a Post
Follow Hub
Disclaimer